JP2022509372A5 - - Google Patents

Info

Publication number
JP2022509372A5
JP2022509372A5 JP2021547670A JP2021547670A JP2022509372A5 JP 2022509372 A5 JP2022509372 A5 JP 2022509372A5 JP 2021547670 A JP2021547670 A JP 2021547670A JP 2021547670 A JP2021547670 A JP 2021547670A JP 2022509372 A5 JP2022509372 A5 JP 2022509372A5
Authority
JP
Japan
Prior art keywords
antibody
sequence
variable domain
amino acid
antibody variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021547670A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509372A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/058286 external-priority patent/WO2020092202A2/en
Publication of JP2022509372A publication Critical patent/JP2022509372A/ja
Publication of JP2022509372A5 publication Critical patent/JP2022509372A5/ja
Priority to JP2024176055A priority Critical patent/JP2024177499A/ja
Pending legal-status Critical Current

Links

JP2021547670A 2018-10-29 2019-10-28 血液脳関門輸送の促進のためのヒト化され安定化されたfc5バリアント Pending JP2022509372A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024176055A JP2024177499A (ja) 2018-10-29 2024-10-07 血液脳関門輸送の促進のためのヒト化され安定化されたfc5バリアント

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862751962P 2018-10-29 2018-10-29
US62/751,962 2018-10-29
PCT/US2019/058286 WO2020092202A2 (en) 2018-10-29 2019-10-28 Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024176055A Division JP2024177499A (ja) 2018-10-29 2024-10-07 血液脳関門輸送の促進のためのヒト化され安定化されたfc5バリアント

Publications (2)

Publication Number Publication Date
JP2022509372A JP2022509372A (ja) 2022-01-20
JP2022509372A5 true JP2022509372A5 (cg-RX-API-DMAC7.html) 2022-11-01

Family

ID=68582454

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547670A Pending JP2022509372A (ja) 2018-10-29 2019-10-28 血液脳関門輸送の促進のためのヒト化され安定化されたfc5バリアント
JP2024176055A Pending JP2024177499A (ja) 2018-10-29 2024-10-07 血液脳関門輸送の促進のためのヒト化され安定化されたfc5バリアント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024176055A Pending JP2024177499A (ja) 2018-10-29 2024-10-07 血液脳関門輸送の促進のためのヒト化され安定化されたfc5バリアント

Country Status (13)

Country Link
US (1) US20220089704A1 (cg-RX-API-DMAC7.html)
EP (1) EP3873934A2 (cg-RX-API-DMAC7.html)
JP (2) JP2022509372A (cg-RX-API-DMAC7.html)
KR (1) KR20210111242A (cg-RX-API-DMAC7.html)
CN (1) CN113508135A (cg-RX-API-DMAC7.html)
AU (1) AU2019371814A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021008105A2 (cg-RX-API-DMAC7.html)
CA (1) CA3117409A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191179A1 (cg-RX-API-DMAC7.html)
IL (1) IL282677A (cg-RX-API-DMAC7.html)
MA (1) MA54070A (cg-RX-API-DMAC7.html)
MX (1) MX2021004772A (cg-RX-API-DMAC7.html)
WO (1) WO2020092202A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
EP4172194A1 (en) * 2020-07-31 2023-05-03 CureVac SE Nucleic acid encoded antibody mixtures
US20250222129A1 (en) * 2022-03-21 2025-07-10 National Research Council Of Canada Lipid Based Nanoparticles for Targeted Gene Delivery to the Brain
CN116650660B (zh) * 2023-07-27 2023-11-03 上海偌妥生物科技有限公司 制备抗体偶联小分子药物的方法及其应用
CN122167571A (zh) * 2024-12-06 2026-06-09 合肥综合性国家科学中心大健康研究院 抗vmat2的抗体或其抗原结合片段及其组合物和应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8620926D0 (en) 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2441903C (en) * 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
WO2006130374A2 (en) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Tweak binding antibodies
PT2548560E (pt) 2005-06-23 2015-09-22 Isis Pharmaceuticals Inc Composições e métodos de modulação da excisão-união de smn2
ATE526345T1 (de) 2005-08-31 2011-10-15 Univ Laval Antikörper und ihre verwendung bei der behandlung,vorbeugung und diagnose einer mit sod1-anomalien assoziierten krankheit
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
HUE033325T2 (en) 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
HRP20150831T1 (hr) 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Fcポリペプチドおよび使用方法
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
PE20121539A1 (es) 2009-06-08 2012-12-06 Amunix Operating Inc Polipeptidos de la hormona de crecimiento y metodos de preparacion
KR20220084437A (ko) 2009-06-17 2022-06-21 바이오젠 엠에이 인코포레이티드 대상에게서 smn2 스플라이싱을 조정하기 위한 조성물 및 방법
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
AU2010311332B2 (en) 2009-10-30 2015-04-23 Albumedix Ltd. Albumin variants
WO2011103076A1 (en) 2010-02-16 2011-08-25 Medlmmune, Llc Hsa-related compositions and methods of use
PH12012501744A1 (en) * 2010-03-03 2021-08-09 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
US20130017997A1 (en) 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
LT2627672T (lt) 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
WO2012059486A1 (en) 2010-11-01 2012-05-10 Novozymes Biopharma Dk A/S Albumin variants
CN103380145B (zh) 2010-12-17 2016-10-12 生物控股有限公司 人类抗-sod1抗体
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
EP2675471A4 (en) 2011-02-15 2015-01-28 Medimmune Llc HSA-RELATED COMPOSITIONS AND USE PROCESSES
WO2012150319A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
PL2723379T3 (pl) 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
SI2766397T1 (sl) 2011-10-11 2018-09-28 F. Hoffmann-La Roche Ag Izboljšano sestavljanje bispecifičnih protiteles
CA2853412C (en) 2011-10-28 2021-05-04 University Of Zurich Tdp-43 specific binding molecules
CN104159922B (zh) * 2012-01-10 2018-03-02 比奥根Ma公司 对转运治疗性分子穿过血脑屏障的增强
CN104302408B (zh) 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
EP2885010B1 (en) 2012-08-16 2020-01-01 Ipierian, Inc. Methods of treating a tauopathy
JP6284548B2 (ja) 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. ヒト抗タウ抗体
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
AU2014217831A1 (en) 2013-02-16 2015-07-16 Albumedix Ltd. Pharmacokinetic animal model
KR102042174B1 (ko) * 2013-03-29 2019-11-08 삼성전자주식회사 인간화 및 친화도 성숙된 항 c-Met 항체 및 그의 용도
WO2014179657A1 (en) 2013-05-03 2014-11-06 Eleven Biotherapeutics, Inc. Albumin variants binding to fcrn
CA2960925A1 (en) 2014-09-30 2016-04-07 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
EP3233922B1 (en) * 2014-12-19 2022-05-11 MedImmune Limited Blood brain barrier transport molecules and uses thereof
AU2016210835B2 (en) * 2015-01-29 2021-01-21 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
WO2017106462A1 (en) 2015-12-18 2017-06-22 Biogen Ma Inc. Bispecific antibody platform
MX389765B (es) * 2016-07-06 2025-03-20 Nat Res Council Canada Anticuerpos humanizados que transmigran a traves de la barrera hematoencefalica y usos de los mismos.
US10906973B2 (en) * 2016-12-12 2021-02-02 National Research Council Of Canada Antibody variants transmigrating the blood-brain barrier and uses thereof
JP7449092B2 (ja) * 2017-01-30 2024-03-13 ナショナル リサーチ カウンシル オブ カナダ 血液脳関門移動化合物及びその使用
CA3059938A1 (en) * 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof

Similar Documents

Publication Publication Date Title
JP6952827B2 (ja) 血液脳関門輸送分子およびそれらの使用
CN104105708B (zh) PDGF受体β结合多肽
US11286312B2 (en) Multispecific antibodies
JP2022518392A5 (cg-RX-API-DMAC7.html)
BR112020004543A2 (pt) proteínas de ligação ativadas condicionalmente restritas
JP2022515424A (ja) 突然変異fabドメインを有する多重特異性結合タンパク質
JP7458327B2 (ja) 血液脳関門移動化合物及びその使用
BR122020025858B1 (pt) Complexo de proteína biespecífico e composição compreendendo o mesmo
EP3129051A1 (en) Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
KR20200027570A (ko) 알파-시누클레인을 인식하는 인간화된 항체
CN111356701A (zh) 抗α-突触核蛋白抗体及其用途
KR101344611B1 (ko) 인간 tweak 에 대한 항체 및 이의 용도
JP2021512159A5 (cg-RX-API-DMAC7.html)
KR20240107202A (ko) 항-트랜스페린 수용체 항체 및 이의 용도
JP2022509372A (ja) 血液脳関門輸送の促進のためのヒト化され安定化されたfc5バリアント
TW202041534A (zh) 基於假Fab的多特異性結合蛋白
EP3551666A1 (en) Antibody variants transmigrating the blood-brain barrier and uses thereof
CA2463616C (en) Affinity enhancement agents
JP2012506237A (ja) Dc−signに対する結合特異性をもつリガンド
JP2019527238A (ja) 薬物送達のための抗体融合タンパク質
EP3674316A1 (en) Multispecific binding proteins with mutant fab domains
EP4480965A1 (en) Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat cns diseases
EP4563586A1 (en) New inhibitors of lrrk2/pp1 interaction
RU2827657C2 (ru) Мультиспецифические связывающие белки с мутантными доменами fab
CA3046906C (en) Antibody variants transmigrating the blood-brain barrier and uses thereof